Japanese Leisure Stock News

TSE:4528
TSE:4528Pharmaceuticals

Assessing Ono Pharmaceutical (TSE:4528) Valuation After Improved Nine Month Earnings

Why Ono Pharmaceutical’s latest earnings matter for shareholders Ono Pharmaceutical (TSE:4528) has drawn fresh attention after reporting nine month results to December 31, 2025, with sales of ¥397,036 million and net income of ¥68,949 million, both above the prior year period. See our latest analysis for Ono Pharmaceutical. The latest nine month earnings update appears to have supported sentiment, with a 1 day share price return of 1.26% and a 30 day share price return of 11.03%. The 1 year...
TSE:9984
TSE:9984Wireless Telecom

SoftBank Group (TSE:9984) TTM Net Margin Spike Tests Bullish Earnings Narratives

SoftBank Group (TSE:9984) just posted its Q3 2026 numbers, with revenue at approximately ¥1.98 trillion and basic EPS of ¥42.76, framing a quarter that sits inside a very earnings heavy trailing twelve months. Over recent periods, revenue has moved from about ¥1.77 trillion in Q2 2025 to ¥1.83 trillion in Q3 2025 and then ¥1.98 trillion in Q3 2026. Trailing twelve month basic EPS has gone from ¥145.28 to ¥641.73, helped by a very large one off gain that lifted the group net margin. For...
TSE:6871
TSE:6871Semiconductor

Micronics Japan (TSE:6871) Valuation After Higher Dividend Proposal And New Earnings Guidance

Dividend proposal and fresh guidance set the stage Micronics Japan (TSE:6871) has proposed an annual cash dividend of ¥95.00 per share for the fiscal year ended December 31, 2025, together with new earnings guidance for the six months to June 30, 2026. The proposed dividend compares with ¥70.00 per share a year earlier and is scheduled for payment from March 27, 2026, subject to approval at the 55th Annual General Meeting of Shareholders on March 26, 2026. At the same time, the company issued...
TSE:9434
TSE:9434Wireless Telecom

SoftBank (TSE:9434) Valuation Check After Quiet Trading And AI Infrastructure Plans

SoftBank (TSE:9434) drew fresh investor attention after its recent trading session, with the share price closing at ¥214.1 as shorter term returns diverged from its stronger multi year track record. See our latest analysis for SoftBank. Recent trading has been relatively quiet, with a small 1 day share price return of 0.80% at ¥214.1. This sits against a modestly weaker year to date share price return and a stronger multi year total shareholder return, which hints that long term momentum has...
TSE:2502
TSE:2502Beverage

Asahi Group Holdings (TSE:2502) Valuation As Cyberattack Effects Linger And Earnings Release Is Rescheduled

Asahi Group Holdings (TSE:2502) has rescheduled its third quarter 2025 earnings release to March 10, 2026 after a cyberattack-related delay, keeping investor attention on how disrupted beer sales and recovering categories feed into the numbers. See our latest analysis for Asahi Group Holdings. At a share price of ¥1,696.5, Asahi Group Holdings has seen a 2.2% 1 month share price return and a 4.9% 3 month share price decline. Its 5 year total shareholder return of 27.85% points to steadier...
TSE:285A
TSE:285ASemiconductor

Kioxia Holdings (TSE:285A) Margin Decline Challenges Bullish Growth Narrative After Q3 2026 Results

Kioxia Holdings (TSE:285A) has just posted another busy quarter, with Q3 2026 revenue of ¥543.6 billion and basic EPS of ¥162.13, setting the tone for how investors will read the rest of this year. The company has seen quarterly revenue move from ¥449.0 billion in Q3 2025 to ¥543.6 billion in Q3 2026, while basic EPS shifted from ¥146.00 to ¥162.13 over the same stretch, giving you a clear sense of how the top and bottom lines have tracked together. With trailing 12 month net profit margins...
TSE:7261
TSE:7261Auto

Why Mazda Motor (TSE:7261) Is Up 9.0% After Swinging To Loss And Cutting Profit Outlook

Mazda Motor Corporation reported earnings for the nine months to December 31, 2025, with sales of ¥3,501,499 million and a net loss of ¥14,710 million, reversing from net income a year earlier and accompanied by a sharply weaker full-year profit outlook. The company linked this downturn to softer global vehicle demand, shifts in US policy, and higher costs, while pressing ahead with its “Multi-Solution Strategy” cost-cutting and supply-chain measures aimed at protecting future...
TSE:4523
TSE:4523Pharmaceuticals

Do Eisai’s (TSE:4523) Rising Sales but Softer Profits Reframe Its Alzheimer’s Investment Story?

In February 2026, Eisai Co., Ltd. held a board meeting to consider the appointment of corporate officers and reported nine-month results to December 31, 2025, with sales of ¥619,950 million and net income of ¥41,808 million. The combination of higher sales yet lower net income and earnings per share than a year earlier highlights rising cost or mix pressures that may concern investors evaluating Eisai’s profitability profile. Next, we’ll explore how Eisai’s higher sales but lower nine-month...
TSE:5711
TSE:5711Metals and Mining

Mitsubishi Materials (TSE:5711) Q3 EPS Surge Tests High P/E Bullish Narratives

Mitsubishi Materials (TSE:5711) Q3 2026 earnings snapshot Mitsubishi Materials (TSE:5711) has reported Q3 2026 revenue of ¥454.6b and basic EPS of ¥236.47, backed by net income of ¥30.9b for the quarter. The company’s revenue moved from ¥494.1b in Q3 2025 to ¥454.6b in Q3 2026, while quarterly EPS shifted from ¥187.54 to ¥236.47 over the same period, against a trailing twelve month EPS of ¥162.93 on revenue of ¥1.76t. This combination of a softer top line and firmer per share earnings focuses...
TSE:1605
TSE:1605Oil and Gas

Inpex (TSE:1605) Margin Resilience Challenges Bearish Earnings Decline Narrative

Inpex (TSE:1605) has just wrapped up FY 2025 with fourth quarter revenue of ¥490,704 million and basic EPS of ¥86.17, while trailing twelve month figures sit at ¥2.0 trillion in revenue and EPS of ¥337.94, giving investors a clear view of both the latest quarter and the full year run rate. Over recent periods, revenue has moved from ¥518,280 million and EPS of ¥115.17 in Q4 2024 to ¥490,704 million and EPS of ¥86.17 in Q4 2025, with trailing net profit margin at 19.6% compared with 18.9% a...
TSE:4506
TSE:4506Pharmaceuticals

Assessing Sumitomo Pharma (TSE:4506) Valuation As AMCHEPRY Faces Key Parkinson’s Disease Review

Sumitomo Pharma (TSE:4506) is back on investors’ radar after Japan’s Ministry of Health, Labour and Welfare scheduled a February 19 committee review of AMCHEPRY, its allogeneic iPS cell derived therapy for advanced Parkinson’s disease. See our latest analysis for Sumitomo Pharma. The upcoming AMCHEPRY review arrives after a volatile few months, with a 10.81% 7 day share price return and a 14.19% 30 day share price decline. At the same time, a very large 1 year total shareholder return of...